Filing summary
Entity note: The supplied 10-Q is for Onconova Therapeutics, Inc., not Traws Pharma, Inc. The filing covers the quarter and six months ended June 30, 2017; confirm that this is the intended filing before relying on the figures below.
Business context and reporting period
Onconova was a clinical-stage biopharmaceutical company focused on oncology. Its principal development effort was rigosertib, including the Phase 3 INSPIRE trial for higher-risk myelodysplastic syndromes (MDS). The interim financial statements are unaudited.
Financial performance and position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | $0.324 million | $2.248 million | $0.534 million | $3.722 million |
| Operating expenses | $6.393 million | $7.647 million | $13.395 million | $16.640 million |
| Operating loss | $6.069 million | $5.399 million | $12.861 million | $12.918 million |
| Net loss | $2.584 million | $5.381 million | $10.925 million | $12.621 million |
| Operating cash used | — | $11.749 million | $8.594 million |
Cash and cash equivalents were $14.989 million at June 30, down from $21.400 million at December 31, 2016. Working capital was approximately $6.1 million. Total assets were $16.100 million, total liabilities $15.658 million, and stockholders’ equity $0.442 million. The balance sheet reports no borrowings or debt; it does report a $1.476 million warrant liability. No meaningful gross margin is presented for this development-stage business.
Six-month financing cash inflow was $5.317 million, principally net proceeds from the April and May 2017 common-stock offering. Net cash decreased $6.411 million over the six months.
Material changes versus the prior comparable period
- Q2 revenue fell $1.924 million year over year, chiefly because Baxalta cost-sharing revenue for INSPIRE ended after its agreement terminated in August 2016. Q2 2017 revenue was from SymBio.
- Q2 operating expenses declined $1.254 million, but operating loss widened by $0.670 million as the revenue decline outweighed the expense reduction. For the first half, lower operating expenses nearly offset lower revenue, leaving operating loss modestly improved.
- Reported Q2 net loss improved largely because of a $3.474 million noncash gain from the change in fair value of warrant liabilities. The six-month warrant fair-value gain was $1.925 million.
- Operating cash use increased by $3.155 million in the first half compared with 2016. Common shares outstanding rose from 6.760 million at year-end 2016 to 9.851 million at June 30, 2017, following equity issuance.
Outlook, commentary, and risks
- Management expected available cash to fund ongoing trials and operations only through the end of 2017 and stated that substantial doubt existed about the company’s ability to continue as a going concern. Additional financing was needed; absent funding, the company might delay, scale back, or stop programs.
- INSPIRE enrollment had slowed. Management expected the interim analysis after 88 deaths, then anticipated in the second half of 2017, more likely the fourth quarter. The data monitoring committee’s prior safety reviews allowed the trial to continue as planned. Full enrollment timing could be delayed.
- On August 9, 2017, the company began transitioning INSPIRE to a new contract research organization, expecting the change to take about 60 days.
- The company would not begin the planned Phase 3 oral rigosertib-plus-azacitidine trial, or further development of certain other rigosertib programs, without additional financing. The earlier ONTIME Phase 3 trial had not met its primary overall-survival endpoint.
- At June 30, stockholders’ equity was below Nasdaq’s $2.5 million minimum requirement, and the company also did not meet the stated alternative standards. The filing said it expected a Nasdaq notice and planned to submit a compliance plan; delisting remained a risk.
- After quarter-end, the estimated warrant liability rose to approximately $2.434 million as of August 14, an estimated $0.958 million increase that would increase net loss.
- No material pending legal proceedings were reported. Management said disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the filing names Onconova Therapeutics, Inc., rather than Traws Pharma, Inc.
- Check subsequent cash, financing, and going-concern disclosures against the stated end-of-2017 cash runway.
- Verify INSPIRE enrollment, interim-analysis timing and outcome, and the operational impact of the CRO transition.
- Track Nasdaq compliance status and any subsequent financing, dilution, or listing developments.
- Review warrant valuation and later-period results, including the disclosed post-quarter increase in estimated warrant liability.